Medcan News

18th February, 2019 – For immediate release

Medcan Australia – Full range of Medcan Australia products available via BHC (Burleigh Heads Cannabis) and CDA (Cannabis Doctors Australia)

Medcan Australia (Medcan) is pleased to announce the delivery of its full range of Medcan Australia branded products to Queensland based Burleigh Heads Cannabis (BHC).

BHC will provide the Medcan Australia product offering to its existing network of national pharmacists and prescribing doctors including the CDA clinic (Cannabis Doctors Australia) medical team. This new order follows on from an initial trial order in late 2019 which saw BHC purchase MEDCAN NQ01 for release to market.

Medcan’s range of products available through BHC and CDA include:


• MEDCAN NQ01 – Dried Flower product – 13% THC

• MEDCAN CC01 – Dried Flower product – 21% THC

• MEDCAN FX01 – Cannabis Oil – 20mg/ml THC

• MEDCAN FX02 – Cannabis Oil – 5mg/ml THC 8mg/ml CBD

• MEDCAN GC01 – Cannabis Capsules – 8mg THC

• MEDCAN GC02 – Cannabis Capsule – 5mg THC, 8mg CBD

Doctors and Pharmacists Australia wide can now access Medcan Australia’s full range of medicinal cannabis products through Burleigh Heads Cannabis.

Patients looking to source the full range of Medcan Australia branded Medicinal Cannabis products, can now contact CDA clinics for medical consultations and advice.

Comments from Craig Cochran – Managing Director, Founder, Medcan Australia:

Medcan Australia Founder, Craig Cochran said: “Medcan, BHC and CDA have been active in the Australian Medicinal Cannabis industry since its inception. We are delighted to now be able to expand our relationships with Dr Ben Jansen, Dr Matua Jansen, Guy Headley and the BHC and CDA team. Only with these types of active collaborations can patient access increase, product affordability increase and the industry advance as a whole.” Craig continued: “The full range of Medcan Australia products being available through BHC and CDA is a testament to the continued commitment of both companies to increase patient access to Medicinal Cannabis products in Australia. Medcan intend to be producing locally cultivated and manufactured products by the 2nd half of 2020 however, to meet the current local demand, have sourced and imported what we believe are the highest quality medicinal cannabis products. We are grateful to have the support of BHC and CDA.”

Comments from Guy Headley – Director of Operations, CDA Health:
“Medcan and BHC have maintained a strong relationship since both entering the Medicinal Cannabis space. We look forward to working with Medcan into 2020 and receiving Australian produced Medan products for our patient base into the second half of the year. Medcan have shown us their commitment towards quality and compliance which is sure to shine through when their in-house products are released. This is another excellent addition to the BHC product portfolio, providing another quality, affordable option for patients and doctors to access across Australia.

Background
Medcan Australia was founded in 2016 and was one of the first Australian companies to be licensed by the Office of Drug Control (ODC) to cultivate and produce Medicinal Cannabis, manufacture Medicinal Cannabis products and import and export Medicinal Cannabis products. The company was founded with a single vision to provide Australian patients with high quality, fair priced Medicinal Cannabis products.

Medcan Australia are one of only a few companies in Australia to hold the full suite of ODC (Office of Drug Control) Licences, State Licences & DAWR Permit being:
1) Cultivation and Production Licence – no. MC013/17
2) Manufacture Licence – no. ML015/18
3) Research Licence – no. RL18/19
4) Import Licence – no. 1821087
5) Export Licence – no. 1821088
6) DAWR Permit – no. 0002005875
7) QLD Health Poison’s Licence – no. AG007354718
8) QLD Wholesaling Approval – no. C-MC-1289
Medcan Australia will be producing a range of high quality Medicinal Cannabis strains with varying CBD & THC profiles to suit varying medicinal applications, with all of our products manufactured under GMP certification, ensuring consistent medicine for patients.

About Burleigh Heads Cannabis and Cannabis Doctors Australia (Cda Clinics)

CDA Health Pty Ltd, through its subsidiaries Burleigh Heads Cannabis Pty Ltd and Cannabis Doctors Australia Pty Ltd provide a market entry solution for local and international producers seeking to access Australia’s Medicinal Cannabis market.

Burleigh Heads Cannabis is a fully licensed wholesaler which utilizes its secure cold-chain facility on the Gold Coast and national pharmacy partner network to provide local and international producers a streamlined importation and distribution service throughout Australia.
CDA operates CDA clinics, doctor-led Medical Cannabis clinics across Australia through its network of physical clinics and Tele-Health consultation services. CDA has completed well over 6000 TGA approvals since launching in October 2018
To learn more visit: www.burleighheadscannabis.com

For further information on Medcan’s expansion plans: https://www.bluemountcapital.com/MCG/

For Further Information please contact:

Gareth Ball +61414860512 Po Box 4579, Springfield, QLD, Australia, 4300 gareth@medcanaustralia.com.au www.medcanaustralia.com.au

29thd January, 2019 – For immediate release

11th of November

10th of October

8th of October 

RAVENQUEST RECEIVES HEALTH CANADA PERMIT FOR EXPORT TO AUSTRALIA       

                                                                                                   

2nd of July 2019

2nd July 2019 Medcan Secured its Research Licence

19th of February 2019

Medcan Looking for new Investors – Press Release FEB 2019.1 (003)